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bjectives We describe initial human experience with a novel cerebral embolic protection device.
ackground Cerebral emboli are the major cause of procedural stroke during percutaneous aortic
alve interventions.
ethods With right radial artery access, the embolic protection device is advanced into the aortic
rch. Once deployed a porous membrane shields the brachiocephalic trunk and the left carotid ar-
ery deﬂecting emboli away from the cerebral circulation. Embolic material is not contained or re-
oved by the device. The device was used in 4 patients (mean age 90 years) with severe aortic
tenosis undergoing aortic balloon valvuloplasty (n  1) or transcatheter aortic valve implanta-
ion (n  3).
esults Correct placement of the embolic protection device was achieved without difﬁculty in all
atients. Continuous brachiocephalic and aortic pressure monitoring documented equal pressures
ithout evidence of obstruction to cerebral perfusion. Additional procedural time due to the use of
he device was 13 min (interquartile range: 12 to 16 min). There were no procedural complications.
re-discharge cerebral magnetic resonance imaging found no new defects in any of 3 patients un-
ergoing transcatheter aortic valve implantation and a new 5-mm acute cortical infarct in 1 asymp-
omatic patient after balloon valvuloplasty alone. No patient developed new neurological symptoms
r clinical ﬁndings of stroke.
onclusions Embolic protection during transcatheter aortic valve intervention seems feasible and
ight have the potential to reduce the risk of cerebral embolism and stroke. (J Am Coll Cardiol
ntv 2010;3:1133–8) © 2010 by the American College of Cardiology Foundation
rom the *Department of Cardiology, St. Paul’s Hospital, Vancouver, British Columbia, Canada; †University of Medicine and
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1134ranscatheter aortic valve interventions are associated
ith a risk of cerebral embolism and stroke. Atheroem-
olism might occur as a consequence of traumatic passage
f wires and catheters around an atheromatous aortic arch
1). Calcific embolism might occur when the endothelial
overing of a degenerated aortic valve is disrupted.
hromboembolism might occur during any interventional
rocedure. Aortic balloon valvuloplasty has been associated
ith a stroke rate of 1% to 4% (2–5). Transcatheter aortic valve
mplantation (TAVI) has been associated with a stroke rate of
.9% to 4.2% (6,7).
See page 1139
Clinical stroke might represent one end of the spectrum of
erebral embolism. Recent studies suggest that subclinical
erebral embolic events are common (8–11). Cranial magnetic
esonance imaging (cMRI) has demonstrated an incidence of
ew cerebral lesions in 22% of elderly high-risk patients
ndergoing diagnostic catheterization with crossing of the
ortic valve (12), and recent studies found that 73% to 84% of
atients undergoing TAVI had new cerebral lesions on cMRI
(13,14). The clinical importance
of asymptomatic new cMRI le-
sions is unknown but remains a
concern (8,15–17).
Cerebral protection devices
exist for carotid interventions
(18) and might lead to a 60%
reduction of brain embolism.
Other devices are currently un-
er investigation for surgical aortic valve replacement (19).
e report our first-in-human experience with the Embrella
mbolic Deflector (Embrella Cardiovascular, Inc., Wayne,
ennsylvania) device, which is designed to reduce the
umber of cerebral emboli in percutaneous aortic valve
nterventions.
Figure 1. Embrella Embolic Deflector
(A) The device consists of a porous membrane (black arrow), a nitinol frame
indicate the end of each petal (black arrows), and one radiopaque marker at
bbreviations
nd Acronyms
MRI  cranial magnetic
esonance imaging
QR  interquartile range
AVI  transarterial aortic
alve implantationsheath (white arrow).ethods
atients. The device was used in 4 patients with severe
ymptomatic aortic stenosis. All patients underwent balloon
ortic valvuloplasty, and in 3 patients this was followed by
AVI. Pre- and post-procedural cMRI studies were per-
ormed. All patients were reviewed by a senior team of
ardiologists and cardiac surgeons and had been declined for
pen aortic valve replacement due to age and comorbidities.
rocedures were approved by the Department of Health and
elfare, Canada, and patients gave written informed con-
ent for TAVI, balloon aortic valvuloplasty, and the use of
he Embrella Embolic Deflector.
mbrella Embolic Deﬂector. The device is designed to cover
he ostia of the brachiocephalic trunk (and its right carotid
ranch) and the left carotid artery originating directly from the
ransverse aorta, thereby deflecting emboli away from the
erebral circulation. Deflecting petals consist of a heparin-
oated polyurethane membrane with 100-m-sized pores.
his membrane is mounted on a Nitinol frame, which itself is
ttached to a 110-cm-long, 0.035-inch (0.09 cm) Nitinol shaft
Fig. 1A). When deployed, the petals of the device extend over
length of 58 mm with a width of 25 mm. Three radiopaque
arkers help fluoroscopy-guided deployment: one at the outer
oint of each petal, and one on the distal shaft (Fig. 1B). The
ntire system can be delivered through a 6-F delivery sheath
ntroduced from the right arm.
Patients were pre-treated with clopidogrel 600 mg and
spirin 325 mg at least 2 h before commencement of the
rocedure. In all patients, a standard 6-F sheath was placed in
he right radial artery, after which heparin was given so as to
chieve an activated clotting time above 300 ms. A 0.035-inch
-tipped guidewire was advanced to the aortic arch, over which
as passed a 90-cm-long 6-F Shuttle SL sheath (Cook
edical, Stouffville, Ontario, Canada). After confirming in-
egrity of the porous membrane of the device by visual
nspection, the device was retracted into a loading tool, flushed,
d arrow), and a nitinol shaft (white arrow). (B) Two radiopaque markers
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1135nd subsequently introduced into the sheath. With the tip of
he sheath in the aortic arch, the device was slowly released
nder fluoroscopic guidance. Deployment of the 2 petals, each
n the opposite direction (one toward the ascending aorta, the
ther toward the distal aortic arch), without deformation of the
etals was assured (Fig. 2). The device was then retracted
oward the sheath so that the distal marker on the sheath
ligned with the radiopaque marker on the device shaft (Figs.
A and 3B). In this position the device and sheath were pulled
ack to cover the ostia of the brachiocephalic trunk and the left
ommon carotid artery, adjacent to the greater curvature of the
ortic arch (Fig. 3C). Correct device position was confirmed if
ontrast injections through the delivery sheath led to temporary
ye pooling over the brachiocephalic and left carotid ostia
djacent to the overlying device (Fig. 3C). Pressure was
easured continuously from the side port of the delivery
heath (representing brachiocephalic pressure distal to the
mbrella device) and from a pigtail in the ascending aorta
representing pressure proximal to the Embrella device) to
nsure that cerebral perfusion was maintained at all time
Fig. 4).
ortic valve intervention. Balloon valvuloplasty was per-
ormed with a balloon (Nucleus, NuMed, Inc., London,
Figure 2. Deployment of Embrella Embolic Deflector
(A) The 2 petals are oriented in the opposite direction. (B) Further deploymen
Figure 3. Final Positioning of Embrella Embolic Deflector
(A, B) The radiopaque marker on the shaft has to be aligned with the radiopa
to cover the ostia of the brachiocephalic trunk and the left common carotid. C
positioning.ntario, Canada) with a nominal diameter equal to the
chocardiographic diameter of the aortic annulus. The
AVI was performed in a standard manner with an
dwards-SAPIEN valve and Retroflex 3 delivery system
Edwards Lifescience, Inc., Irvine, California) (20). Percu-
aneous femoral access was used. A 14-F arterial sheath was
sed in the 1 patient undergoing valvuloplasty alone, a 24-F
heath (for the 26-mm Edwards-SAPIEN valve) was used
n 2 patients, and a 22-F sheath (for the 23-mm Edwards-
APIEN valve) was used in 1 patient. Percutaneous punc-
ure with pre-closure of the femoral access site (ProGlide,
bbott Vascular, Abbott Park, Illinois) was routine. Rapid
acing during balloon valvuloplasty and TAVI was routine.
eneral anesthesia with transesophageal echo-guidance was
sed in all TAVI procedures.
tatistics. All data are presented, given the small study
opulation, as median and interquartile range (IQR). No
roup comparisons were performed.
esults
aseline characteristics. Median age was 90 years (IQR: 87
o 92 years), 3 men and 1 woman. Risk factors for stroke
the 2 petals fully opened.
arker on the tip of the sheath. (C) The sheath and the device are retracted
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1136ncluded peripheral vascular disease in 2, prior stroke in 3,
ypertension in 3, and dyslipidemia in 2; none suffered
iabetes or was a smoker, and none had severe ascending
orta calcification (21). Fluoroscopic calcification of the
scending aorta was graded mild in all, and fluoroscopic
alvular calcification was graded 3 (dense circumferential
alcification) in 3 patients.
rocedural outcome. Correct placement of the Embrella
mbolic Deflector with the deflecting petals covering the
rachiocephalic and left carotid artery ostia was achieved in
ll 4 patients. The device seemed to be self-aligning within
he transverse aorta and did not require manipulation
eyond withdrawal to appose the outer curvature of the
ortic arch. Contrast injection through the delivery sheath
onfirmed transient pooling in the arch vessels distal to the
eflector. Radial and aortic monitoring showed no signifi-
ant reduction in perfusion pressure and did not vary
hrough the course of the procedure (Fig. 4).
Advancement of wires, pigtail catheters, valvuloplasty
alloons, and the relatively bulky valve delivery system
longside the Embrella device was associated with minimal
nteraction without significant interference or dislodgement
f the device (Fig. 5). In 1 case a wire and pigtail catheter
eemed to pass behind the deflector. This was corrected by
urther withdrawing the deflector to improve apposition of
Figure 4. Continuous Pressure Recording Proximal and Distal to Device
Three pressure tracings were continuously recorded: aortic pressure (green), b
sure gradient across the device.he device. At the end of the valve procedures, the deflectoras easily withdrawn into the delivery sheath and removed.
emostasis was accomplished with a standard radial compres-
ion band. Device inspection showed no evidence of visible
cephalic pressure (blue), and femoral pressure (purple). There was no pres-
Figure 5. Minimal Device Interference
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1137amage or adherent thrombus or embolic material (Fig. 6).
he total procedural time was 91.5 min (IQR: 83 to 97
in). Total time for insertion of the radial sheath, subse-
uent exchange for the Shuttle SL sheath and insertion,
lacement, and finally retrieval of the Embrella device was
3 min (IQR: 12 to 16 min). The Embrella deflector was
eployed (“device in patient”) for a total of 42 min (IQR: 39
o 50 min).
linical outcome. Clinical assessment before hospital dis-
harge did not reveal any new neurologic symptoms. No
rocedural complications occurred; in particular there were
o complications related to insertion of the Embrella device.
re-discharge cMRI showed a 5-mm acute cortical infarct
n the right temporal lobe in the patient that underwent
alloon aortic valvuloplasty alone. No patient undergoing
AVI had a new finding on pre-discharge cMRI.
iscussion
ur first-in-human experience demonstrates that cerebral
mbolic protection during transcatheter aortic valve inter-
entions is feasible and can be accomplished without sig-
ificantly interfering with or prolonging what is an already
omplex procedure.
The Embrella device has a number of advantageous
eatures. It can be introduced easily from the radial artery
ith minimal interference with the course of the TAVI
rocedure. Protection during the entire course of a TAVI
rocedure is feasible. A single device provides protection for
he right carotid and right vertebral branches of the bra-
hiocephalic artery and the left carotid artery. In some
atients, the device might also overlie the left subclavian
stium, providing protection for the left vertebral. Because
he device is not positioned within the cerebral vessels, the
isk of arterial spasm, injury, thrombosis, or transiently
Figure 6. Device Integrity
No damage to the device was observed after retrieval.mpaired cerebral perfusion seems minimal. wCerebral emboli originating from the aortic valve and
roximal aorta are likely the major mechanism of stroke in
he setting of aortic valve intervention (12–14). Although
troke rates were relatively high in the early TAVI experi-
nce, the reported risk of stroke seems to be falling, perhaps
ue to the development of less traumatic valve delivery
atheters (22,23), improved technique, and patient selec-
ion. Nevertheless, recent TAVI series continue to report a
% to 4% risk of clinical stroke associated with significant
orbidity and mortality (6,7,23).
Several lines of evidence suggest that reported stroke rates
ight underestimate the clinical importance of cerebral
mbolism. Early experience with transcranial Doppler and
ost-procedural cMRI (13,14) suggests that cerebral embo-
ism is more the norm than the exception with TAVI, even
n the absence of clinical deficits. Comparable experience
ith carotid stenting suggests microemboli play a role in
emory loss and other neurocognitive syndromes (24,25).
everal studies suggest that cerebral protection during
arotid interventions might reduce cerebral embolism and
mprove outcomes (18,26–28).
The current study documents use of the Embrella device
n the setting of TAVI. However, other potential applica-
ions can be envisioned. Open heart or aortic surgery in the
resence of aortic atheroma or intracardiac thrombus and
itral valvuloplasty or atrial appendage closure in the
resence of left atrial thrombus might represent additional
otential applications for cerebral protection.
tudy limitations. Our experience can only be considered a
roof of concept, given the small number of patients.
urther studies will be required to document safety and
fficacy. All our patients had type II aortic arch anatomy
ith the right subclavian and right carotid artery originating
rom the brachiocephalic trunk. The importance of variation
n aortic arch anatomy is unknown, as is the applicability of
his device in patients undergoing aortic valve interventions
ith different interventional devices and routes of access
e.g., transaxillary or transapical). The risk of device throm-
osis in the presence of suboptimal anticoagulant and
ntiplatelet therapy and prolonged dwell time are unknown.
n obvious concern is that this device does not trap emboli
r allow for their removal. Instead emboli are deflected into
he descending aorta. Although cerebral embolization
ight be reduced, embolization to the periphery, kidneys,
nd bowel might be correspondingly increased. Theoreti-
ally the clinical consequences are less with peripheral
icroembolism; however, this remains to be demonstrated.
onclusions
he use of an aortic embolic deflector system seems feasible
nd is compatible with clinical aortic valvuloplasty and
ranscatheter valve implantation. The procedure seems safe
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1138mbolic Deflector is a promising device that might improve
he outcomes of TAVI. Further studies are required to
urther assess safety and efficacy.
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